ADDLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.8 SEK | -0.10% |
|
-8.60% | -10.60% |
| Feb. 12 | Nordic Shares Rose Monday; FastPartner Series A Topped Leaders | DJ |
| Feb. 02 | Transcript : AddLife AB, 2023 Earnings Call, Feb 02, 2024 |
| Sales 2024 * | 10.12B 922M | Sales 2025 * | 10.77B 981M | Capitalization | 11.92B 1.09B |
|---|---|---|---|---|---|
| Net income 2024 * | 281M 25.59M | Net income 2025 * | 436M 39.71M | EV / Sales 2024 * | 1.62 x |
| Net Debt 2024 * | 4.49B 409M | Net Debt 2025 * | 3.83B 349M | EV / Sales 2025 * | 1.46 x |
| P/E ratio 2024 * |
42.4
x | P/E ratio 2025 * |
27.3
x | Employees | 2,301 |
| Yield 2024 * |
0.82% | Yield 2025 * |
1.38% | Free-Float | 87.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on AddLife AB
| 1 day | -0.10% | ||
| 1 week | -8.60% | ||
| Current month | -12.68% | ||
| 1 month | -4.59% | ||
| 3 months | -5.87% | ||
| 6 months | +71.58% | ||
| Current year | -10.60% |
1 week
96.20
103.50
1 month
96.20113.70
Current year
94.65118.40
1 year
54.75143.40
3 years
54.75395.00
5 years
52.25395.00
10 years
24.25395.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Dalborg
CEO | Chief Executive Officer | 52 | 21-12-31 |
| Director of Finance/CFO | - | 21-12-31 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 20-12-31 | |
Johan Olov Sjö
CHM | Chairman | 57 | 15-03-04 |
| Director/Board Member | 69 | 14-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 97.8 | -0.10% | 66,296 |
| 24-04-17 | 97.9 | -1.41% | 55,041 |
| 24-04-16 | 99.3 | -2.55% | 60,259 |
| 24-04-15 | 101.9 | -1.07% | 129,523 |
| 24-04-12 | 103 | -3.74% | 217,154 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT
More quotes
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
97.8
SEK
Average target price
134.5
SEK
Spread / Average Target
+37.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.60% | 1.09B | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- ALIF B Stock
